高级搜索

国内外头颈部鳞癌指南循证评价(鼻咽癌除外)

蒋艳明, 朱小东, 周支瑞, 曲 颂

在线预览 下载 (1.1MB)
蒋艳明, 朱小东, 周支瑞, 曲 颂. 国内外头颈部鳞癌指南循证评价(鼻咽癌除外)[J]. 肿瘤防治研究, 2014, 41(04): 446-452. DOI: 10.3971/j.issn.1000-8578.2014.04.040
引用本文: 蒋艳明, 朱小东, 周支瑞, 曲 颂. 国内外头颈部鳞癌指南循证评价(鼻咽癌除外)[J]. 肿瘤防治研究, 2014, 41(04): 446-452. DOI: 10.3971/j.issn.1000-8578.2014.04.040
shu
JIANG Yanming, ZHU Xiaodong, ZHOU Zhirui, QU Song. Evidence-based Evaluation of Global Guidelines for Head and Neck Squamous Cell Carcinoma (Excepting Nasopharynx Cancer)[J]. Cancer Research on Prevention and Treatment, 2014, 41(04): 446-452. DOI: 10.3971/j.issn.1000-8578.2014.04.040
Citation: JIANG Yanming, ZHU Xiaodong, ZHOU Zhirui, QU Song. Evidence-based Evaluation of Global Guidelines for Head and Neck Squamous Cell Carcinoma (Excepting Nasopharynx Cancer)[J]. Cancer Research on Prevention and Treatment, 2014, 41(04): 446-452. DOI: 10.3971/j.issn.1000-8578.2014.04.040
shu

国内外头颈部鳞癌指南循证评价(鼻咽癌除外)

  • 530021 南宁，广西医科大学附属肿瘤医院放疗科

详细信息
    作者简介:

    蒋艳明（1986-），女，硕士，主要从事头颈部肿瘤的临床放疗研究

    通信作者:

    朱小东，E-mail: Zhuxiaodong83@163.com

  • 中图分类号: R739.91

Evidence-based Evaluation of Global Guidelines for Head and Neck Squamous Cell Carcinoma (Excepting Nasopharynx Cancer)

  • Department of Radiation Oncology, Cancer Hospital of Guangxi Medical University, Nanning, 530021, China

摘要

    摘要
  • 摘要: 目的 了解国内外头颈部鳞癌指南的发布状况、评价其质量，为我国制定头颈部鳞癌指南提供借鉴。方法 计算机检索PubMed、Embase、NGC(U.S. National Guideline Clearing-house), CMA Infobase(the Canadian Medical Association Infobase), GIN(the Guidelines International Network), SIGN(the Scottish Intercollegiate Guidelines Network), the CMAdisc等中英文数据库和指南网站，按既定的纳入与排除标准，筛选文献，纳入符合标准的指南，用指南评价工具AGREE( Appraisal of Guideline for REsearch and Evaluation) Ⅱ对其进行质量评价。结果 共检索出514篇相关文献，最终纳入49篇头颈部鳞癌指南，共覆盖15个国家、地区。现有指南主要由美国、加拿大、英国发布。49篇指南6个领域的得分分别为：71.63%、43.37%、45.63%、68.08%、32.41%、42.55%。结论 国内外头颈部鳞癌指南的质量中等，国内可借鉴AGREE的评价体系结合国内实际制定高水平的临床指南。
    Abstract: Objective To review and evaluate the basic contents and development of the current global clinical guidelines for head and neck squamous cell carcinoma. Methods　Seven databases, PubMed, Embase, NGC(U.S. National Guideline Clearing-house), CMA infobase(the Canadian Medical Association Infobase), GIN(the Guidelines International Network), SIGN(the Scottish Intercollegiate Guidelines Network) and the CMAdisc, were screened according to the predefi ned inclusion and exclusion criteria. The number of clinical guidelines was counted and the quality of guidelines was also assessed by AGREE( Appraisal of Guideline for REsearch and Evaluation) Ⅱ. Results　A total of 514 articles were found to be clinical guideline-related and 49 articles were fi nally included. The guidelines were issued by 15 countries/regions, mainly by American, Canada and UK. Mean scores of six domains were 71.63%, 43.37%, 45.63%, 68.08%, 32.41% and 42.55%, respectively. Conclusion　The quality of otorhinolaryngology guidelines in China is not high. China can be drawn lessons from the AGREE system and combined with domestic actual condition to making high level clinical guidelines.
    • HTML全文
    • 参考文献(55)
  • [1] AGREE next steps consortium (2009). The AGREE II instrument (Electronic version), 2011.
    [2] Chen yi, Hu shilian, Li youping, et al. Guidelines concerning pharmacological intervention in simple hypertension: a systematic review[J].Zhongguo Xun Zheng Yi Xue Za Zhi, 2012, 12(10): 11 80-94.[陈尹, 胡世莲, 李幼平,等.全球药物干预治疗单纯性高 血压指南的系统评价[J].中国循证医学杂志，2012,12（10）： 11 80-94.]
    [3] Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability[J]. Psychol Bull, 1979, 86(2): 420-8.
    [4] Chen YL,Yao L,Xiao XJ,et al.Quality assessment of clinical guidelines in China:1993-2010[J]. Chin Med J(Engl), 2012, 12 5(20): 3660-4.
    [5] Zhang ZW, Liu XW, Xu BC, et al.Analysis of quality of clinical practice guidelines for otorhinolaryngology in China[J]. PloS One, 2013,8(1): e53566.
    [6] Alonso-Coello P, Irfan A, Solà I, et al. The quality of clinical practice guidelines over the last two decades: a systematic review of guideline appraisal studies[J]. Qual Saf Health Care,2010, 19 (6): e58.
    [7] Burgers JS, Fervers B, Haugh M, et al. International assessment of the quality of clinical practice guidelines in oncology using the Appraisal of Guidelines and Research and Evaluation Instrument[J]. J Clin Oncol, 2004, 22(10): 2000-7.
    [8] Expert Panel on Radiation Oncology-Head & Neck Cancer, Yeung AR, Garg MK, et al. ACR Appropriateness Criteria® ipsilateral radiation for squamous cell carcinoma of the tonsil[J]. Head Neck, 20 12, 34(5): 613-6.
    [9] Rethman MP, Carpenter W, Cohen EE, et al. Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas[J]. Tex Dent J, 2012, 129(5): 491-507.
    [10] Bernier J, Russi EG, Homey B, et al. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines[J]. Ann Oncol, 2011, 22(10): 2191-200.
    [11] Mesía Nin R, Pastor Borgoñón M, Cruz Hernández JJ, et al. SEOM clinical guidelines for the treatment of head and neck cancer[J]. Clin Transl Oncol, 2010, 12(11): 742-8.
    [12] Grégoire V, Lefebvre JL, Licitra L, et al. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 20 10, 21 Suppl 5: v184-6.
    [13] Quon H, Yom SS, Garg MK,et al. ACR Appropriateness Criteria: local-regional therapy for resectable oropharyngeal squamous cell carcinomas[J]. Curr Probl Cancer, 2010, 34(3): 175-92.
    [14] Ramos M,Benavente S,Giralt J. Management of squamous cell carcinoma of the head and neck: updated European treatment recommendations[J]. Expert Rev Anticancer Ther, 2010, 10(3): 33 9-44.
    [15] Wee JT, Anderson BO, Corry J,et al. Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009[J]. Lancet Oncol, 2009, 10(11): 1086-92.
    [16] Alkureishi LW, Burak Z, Alvarez JA,et al. Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma[J]. Ann Surg Oncol, 2009, 16(11): 3190-210.
    [17] Porceddu SV, Sidhom M, Foote M, et al. Predicting regional control based on pretreatment nodal size in squamous cell carcinoma of the head and neck treated with chemoradiotherapy: a clinician’s guide[J]. J Med Imaging Radiat Oncol, 2008, 52(5): 49 1-6.
    [18] Chopra S, Gupta T, Agarwal JP, et al. Re-irradiation in the management of isolated neck recurrences: current status and recommendations[J]. Radiother Oncol, 2006, 81(1):1-8.
    [19] Bilde A, von Buchwald C, Johansen J, et al. The Danish national guidelines for treatment of oral squamous cell carcinoma[J]. Acta Oncol, 2006, 45(3): 294-9.
    [20] Grégoire V, Eisbruch A, Hamoir M, et al. Proposal for the delineation of the nodal CTV in the node-positive and the postoperative neck[J]. Radiother Oncol, 2006, 79(1): 15-20.
    [21] Hamoir M, Vander Poorten V, Chantrain G, et al. Initial work-up in head and neck squamous cell carcinoma[J]. B-ENT, 2005, 1: 12 9-32.
    [22] Mazeron JJ, Ardiet JM, Haie-Méder C, et al. GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas[J]. Radiother Oncol, 2009, 91(2): 150-6.
    [23] Brown J, Chatterjee R, Lowe D, et al. A new guide to mandibular resection for oral squamous cell carcinoma based on the Cawood and Howell classifi cation of the mandible[J]. Int J Oral Maxillofac Surg, 2005, 34(8): 834-9.
    [24] Hodson DI, Browman GP, Thephamongkhol K, et al. The role of amifostine as a radioprotectant in the management of patients with squamous cell head and neck cancer[J]. Current Oncology, 2003, 10 (3): 146-60.
    [25] Cancer Care Ontario. Hyperfractionated radiotherapy for locally advanced squamous cell carcinoma of the head and neck[OL]. Toronto, Ontario: Cancer Care Ontario,2003.
    [26] Yoo J, Lacchetti C, Hammond A, et al. The role of endolaryngeal surgery (with or without laser) versus radiotherapy in the management of early (T1) glottic cancer[OL].Toronto, Ontario: Cancer Care Ontario,2012.
    [27] Expert Panel on Radiation Oncology-Head and Neck, Salama JK, Saba N, et al. ACR Appropriateness Criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck[J]. Oral Oncol, 2011,47(7):554-9.
    [28] Orphanidou C, Biggs K, Johnston ME, et al. Prophylactic feeding tubes for patients with locally advanced head-and-neck cancer undergoing combined chemotherapy and radiotherapy-systematic review and recommendations for clinical practice[J]. Curr Oncol, 20 11, 18(4):e191-201.
    [29] O’Sullivan B, Rumble RB, Warde P. The role of IMRT in head and neck cancer[OL]. Toronto, Ontario: Cancer Care Ontario,2011.
    [30] McDonald MW, Lawson J, Garg MK, et al. ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior defi nitive radiation expert panel on radiation oncology-head and neck cancer[J].Int J Radiat Oncol Biol Phys,2011, 80(5):1292-8.
    [31] Dutch Head and Neck Oncology Cooperative Group.Hypopharyngeal cancer[OL].Netherlands:Dutch Head and Neck Oncology Cooperative Group,2007.
    [32] Kaanders JH, Hordijk GJ, Dutch Cooperative Head and Neck Oncology Group. Carcinoma of the larynx: the Dutch national guideline for diagnostics, treatment, supportive care and rehabilitation[J]. Radiother Oncol,2002, 63(3):299-307.
    [33] GUIDELINE POFT. The management of head and neck cancer in ontario: organizational and clinical practice guideline recommendations[OL]. Toronto, Ontario: Cancer Care Ontario,2009.
    [34] Cripps C, Winquist E, Devries MC, et al. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer[J]. Curr Oncol, 2010, 17(3): 37-48.
    [35] Greenhalgh J,Bagust A,Boland A,et al.Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck[J].Health Technol Assess,2009,13 Suppl 3:49-54.
    [36] Cancer Care Ontario. PET imaging in head and neck cancer[OL]. Toronto, Ontario: Cancer Care Ontario,2012.
    [37] Health Partners Dental Group.Health Partners Dental Group and Clinics oral cancer guideline[OL].Minneapolis, American: Health Partners Dental Group,2007.
    [38] Scottish Intercollegiate Guidelines Network. Diagnosis and management of head and neck cancer. A national clinical guideline[internet]. Edinburgh, Scotland:Scottish Intercollegiate Guidelines Network,2006.
    [39] American Society of Clinical Oncology, Pfister DG, Laurie SA,et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer[J].J Clin Oncol,2006, 24 (22):3693-704.
    [40] National Institute for Clinical Excellence. Improving outcomes in head and neck cancers (CSGHN) [OL].London: National Institute for Clinical Excellence,2004.
    [41] British Association of Head and Neck Oncologists. Practice care guidance for clinicians participating in the management of head and neck cancer patients in the UK. Drawn up by a Consensus Group of Practising Clinicians[J]. Eur J Surg Oncol, 2001, 27 Suppl A:S1-17.
    [42] Manikantan K, Khode S, Dwivedi RC, et al. Making sense of posttreatment surveillance in head and neck cancer: when and what of follow-up[J]. Cancer Treat Rev, 2009, 35(8):744-53.
    [43] Cancer Care Ontario. The role of post-operative chemoradiotherapy for squamous cell carcinoma of the head and neck[OL].Toronto, Ontario: Cancer Care Ontario,2004.
    [44] Cancer Care Ontario. Symptomatic treatment of radiation-induced xerostomia in head and neck cancer patients[OL].Toronto, Ontario: Cancer Care Ontario,2004.
    [45] Tolentino Ede S, Centurion BS, Ferreira LH, et al. Oral adverse effects of head and neck radiotherapy: literature review and suggestion of a clinical oral care guideline for irradiated patients[J]. J Appl Oral Sci,2011, 19(5):448-54.
    [46] British Association of Otolaryngology. Head and Neck Cancer[OL].British: British Association of Otolaryngology,2011.
    [47] National Comprehensive Cancer Network. Head and neck cancer[OL].American: National Comprehensive Cancer Network,2012.
    [48] Cancer Care Ontario. The role of neoadjuvant chemotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck (excluding nasopharynx) [OL].Toronto, Ontario: Cancer Care Ontario,2003.
    [49] British Columbia Cancer Agency.Head and neck cancer management guidelines[OL].British: British Columbia Cancer Agency,2003.
    [50] Clinical Oncological Society of Australia. Evidence Based Guidelines for the Nutritional Management of Patients with Head and Neck Cancer[OL].Australia: Clinical Oncological Society of Australia,2011.
    [51] Jack DR, Dawson FR, Reilly JE, et al. Guideline for prophylactic feeding tube insertion in patients undergoing resection of head and neck cancers[J]. J Plast Reconstr Aesthet Surg,2012, 65(5):610-5.
    [52] Salama JK, Haddad RI, Kies MS, et al. Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer[J]. Int J Radiat Oncol Biol Phys,2009,75(3):725-33.
    [53] Robbins KT, Shaha AR, Medina JE, et al. Consensus statement on the classifi cation and terminology of neck dissection[J]. Arch Otolaryngol Head Neck Surg, 2008, 134(5): 536-8.
    [54] British Columbia Oral Cancer Prevention Program, BC Cancer Agency; College of Dental Surgeons of British Columbia. Guideline for the early detection of oral cancer in British Columbia 2008[J]. J Can Dent Assoc, 2008,74(3):245.
    [55] Renaud-Salis JL,Blanc-Vincent MP,Brugère J,et al. Epidermoid cancers of the oropharnyx[J]. Br J Cancer, 2001,84 Suppl 2:37-41.
    • 相关文章
    • 施引文献
    • 资源附件(0)
在线预览 下载 (1.1MB)
计量
  • 文章访问数:  2121
  • HTML全文浏览量:  523
  • PDF下载量:  726
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-12-06
  • 修回日期:  2013-04-15
  • 刊出日期:  2014-04-24

目录

摘要
HTML全文
    参考文献(55)
    相关文章
    施引文献
    资源附件(0)
    QU Song

    • Department of Radiation Oncology, Cancer Hospital of Guangxi Medical University, Nanning, 530021, China

    1. On this Site
    2. On Google Scholar
    3. On PubMed

    /

    返回文章
    返回

    下载中心

    友情链接

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：22300159 今日访问：38814

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭